The Prostate Cancer Program (Program) of the UCSF Helen Diller Family Comprehensive Cancer (Center) is a multidisciplinary group of investigators focused on understanding the core biology that drives the clinical behavior of prostate cancer across the full spectrum of the disease. The Prostate Cancer Program comprises 25 basic and clinical scientists from nine departments working together to translate research into advances in the epidemiology, prevention, staging, and treatment of prostate cancer. Program faculty represent membership in five graduate programs: Program in Biological Sciences (PIBS);Biomedical Sciences (BMS);Bioengineering, Pharmaceutical Sciences and Pharmacogenomics (PSPG);and Chemical Biology. The goals of the Program are to promote interdisciplinary research that will allow a better understanding ofthe biology of prostate cancer from the biologic and environmental factors associated with carcinogenesis, through the early detection and disease progression to prognostication, and the biologic basis of disease progression. The ultimate goal is the development of novel intervention strategies that will improve the lives of men who carry a diagnosis of prostate cancer or who are at risk of developing prostate cancer. The Prostate Cancer Program pursues these goals through ongoing work in four major thematic areas: (1) Risk and Oncogenesis;(2) Prognosis and Progression;(3) Biology and Therapeutic Targets;and (4) Disparities, Health Related Quality of Life (HRQOL), and Outcomes. The Program has $9,667,568 in total peer reviewed support for the last grant year. The Program has 16% intra-programmatic and 13% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693934
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$143
Indirect Cost
$53
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
John, Constance M; Phillips, Nancy J; Din, Richard et al. (2016) Lipooligosaccharide Structures of Invasive and Carrier Isolates of Neisseria meningitidis Are Correlated with Pathogenicity and Carriage. J Biol Chem 291:3224-38
Shatsky, Maxim; Dong, Ming; Liu, Haichuan et al. (2016) Quantitative Tagless Copurification: A Method to Validate and Identify Protein-Protein Interactions. Mol Cell Proteomics 15:2186-202
Nordström, Tobias; Van Blarigan, Erin L; Ngo, Vy et al. (2016) Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 76:339-48
Bulut-Karslioglu, Aydan; Biechele, Steffen; Jin, Hu et al. (2016) Inhibition of mTOR induces a paused pluripotent state. Nature 540:119-123
Akutagawa, J; Huang, T Q; Epstein, I et al. (2016) Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia 30:1335-43
Baeza-Raja, Bernat; Sachs, Benjamin D; Li, Pingping et al. (2016) p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. Cell Rep 14:255-68
Ko, Andrew H; Bekaii-Saab, Tanios; Van Ziffle, Jessica et al. (2016) A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res 22:61-8
Nosbaum, Audrey; Prevel, Nicolas; Truong, Hong-An et al. (2016) Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing. J Immunol 196:2010-4
Phan, An T; Fernandez, Samantha G; Somberg, Jessica J et al. (2016) Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels. Biochem Biophys Res Commun 474:71-5
Chang, Matthew T; Asthana, Saurabh; Gao, Sizhi Paul et al. (2016) Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34:155-63

Showing the most recent 10 out of 135 publications